Teveten HCT (Eprosartan Mesylate Hydrochlorothiazide Tablets)由Pharmaceuticals开发，商品名：Teveten HCT，于2001年11月获得FDA批准，适应征是高血压。     
依普罗沙坦为选择性的、非二苯基、非四唑类血管紧张素Ⅱ受体拮抗剂。通过拮抗血管紧张素Ⅱ发挥作用，阻滞血管紧张素醛固酮系统激活，来抑制血压升高。由史克必成公司开发，其商品名为Teveten。Smithkline Beechan公司研制，荷兰solvay公司获许可，于1997年7月首先在德国上市，商品名为Teveten；1997年12月美国FDA批准ABBOTT (雅培)在美上市；2 0 0 0年在英国和澳大利亚上市。甲磺酸依普罗沙坦/氢氯噻嗪2001年12月美国FDA批准ABBOTT (雅培)在美上市。国内进口，依普沙坦片，H20070400 ，solvay公司进口
TEVETEN HCT Rx
Generic Name and Formulations:
Eprosartan (as mesylate), hydrochlorothiazide; 600mg/12.5mg, 600mg/25mg; tabs.

Company:
AbbVie

Indications for TEVETEN HCT:
Hypertension (not for initial therapy).

Adult:
May be substituted for titrated components. ≥18yrs: One Teveten HCT 600mg/12.5mg tab once daily; after 2–3 weeks may increase to one Teveten HCT 600mg/25mg tab once daily. May add eprosartan 300mg once daily in the PM if additional BP control is needed at trough. Moderate-to-severe renal impairment: max 600mg daily.

Children:
<18yrs: not established.

Contraindications:
Anuria. Sulfonamide allergy. Concomitant aliskiren in patients with diabetes.

Warnings/Precautions:
Fetal toxicity may develop; discontinue if pregnancy is detected. Correct salt/volume depletion before starting, or monitor closely. Hepatic dysfunction. Renal impairment: monitor for worsening renal function. Renal artery stenosis. Severe CHF. Asthma. Diabetes. Postsympathectomy. SLE. Gout. Acute myopia and secondary angle-closure glaucoma. Monitor BP, electrolytes. Elderly. Neonates. Pregnancy (Cat.D); avoid. Nursing mothers: not recommended.

Interactions:
See Contraindications. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; avoid. Avoid concomitant aliskiren in renal impairment (CrCl <60mL/min). Hyperkalemia with K+ supplements, K+ sparing diuretics, or K+ containing salt substitutes. May be antagonized by, and renal toxicity potentiated by NSAIDs, including COX-2 inhibitors; monitor renal function periodically in elderly and/or volume-depleted. Adjust antidiabetic, antigout medications. ACTH, corticosteroids increase hypokalemia risk. Orthostatic hypotension potentiated by alcohol, CNS depressants. Reduced absorption with bile acid resins (eg, cholestyramine, colestipol). Potentiates other antihypertensives. May potentiate nondepolarizing muscle relaxants. May interfere with parathyroid tests. May antagonize norepinephrine. May increase lithium levels; monitor.

Pharmacological Class:
Angiotensin II receptor blocker + thiazide diuretic.

Adverse Reactions:
Dizziness, back pain, orthostatic hypotension, electrolyte disturbances, adverse lipid values, rhabdomyolysis (rare).

Metabolism:
Hepatic. 98% protein bound.

Elimination:
Renal, biliary.

Generic Availability:
NO

How Supplied:
Tabs—100
------------------------------------
附件：